Rheumatoid Arthritis Ra Epidemiology Forecast

DelveInsight's “Rheumatoid Arthritis- Epidemiology Forecast–2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Geography Covered

  • The United States
  • EU4 (Germany, France, Italy, and Spain), and the United Kingdom
  • Japan

Study Period: 2019-2032

Rheumatoid Arthritis Disease Understanding

Rheumatoid Arthritis Overview

RA is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. RA is the result of an immune response in which the body's immune system attacks its own healthy cells and the specific causes of RA are still unknown.

 

RA is more common in women and about 75% of RA patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.

 

RA is a chronic disease that causes joint pain, stiffness, swelling, and decreased movement of the joints. Small joints in the hands and feet are most commonly affected. Sometimes RA can affect other organs such as the eyes, skin, or lungs.

 

Rheumatoid Arthritis Diagnosis

Typically, RA is diagnosed by a combination of the patient's symptoms, results of the doctor´s examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies. 

Rheumatoid Arthritis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of RA, total diagnosed prevalent cases of RA, gender-specific prevalent cases of RA, age-specific prevalent cases of RA, severity-specific prevalent cases of RA, patients on targeted therapies of RA, line-wise treated cases of RA in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032.

 

Key Findings

This section provides a glimpse of the RA epidemiology in the 7MM

Rheumatoid Arthritis Epidemiology

The epidemiology segment provides the RA epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

  • The total prevalent population of RA in the 7MM comprised 4,724,978 cases in 2021 and is projected to increase during the forecast period.
  • The total diagnosed prevalent cases of RA in the US were 1,256,779  in 2021
  • The United States contributed to the largest diagnosed cases of RA, accounting for ~ 30% of the 7MM in 2021.
  • Among EU4 countries, Germany accounted for the highest number of RA cases, whereas France accounted for the lowest number of cases in 2021.
  • In Japan, the total diagnosed prevalent population of RA was 924,571 in 2021.
  • In 2021, males and females accounted for 301,627 and 955,152 cases respectively in the United States.
  • In the United States, the total age-specific prevalent cases of RA were 61,834, 134,098, 297,605, 438,365, and 324,877 cases for the age group 18-34 years, 35-44 years, 45-54 years, 55-64 years, and ≥65 years in 2021.
  • In 2021, 377,034 mild cases, and 879,745 moderate-to-severe cases were observed in the United States

Scope of the Report

  • The report covers a descriptive overview of RA, explaining its causes, signs and symptoms, pathogenesis, and diagnosis.
  • Comprehensive insight has been provided into RA epidemiology and treatment.
  • The report provides insight into the historical and forecasted patient pool of RA in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • A detailed review of the RA epidemiology forecast is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding epidemiological trends.

Report Highlights

  • In coming years, the RA market is anticipated to change owing to the improvement in the diagnosis methodologies, raising awareness of the disease, and increase in the prevalent population.
  • As per DelveInsight’s analysis, on the basis of severity RA is categorized into mild, moderate, and severe.
  • The report also encompasses other major segments, i.e., total prevalent cases of RA, total diagnosed prevalent cases of RA, gender-specific prevalent cases of RA, age-specific prevalent cases of RA, severity-specific prevalent cases of RA, patients on targeted therapies of RA, and line-wise treated cases of RA.

RA Report Insights

  • Patient Population
  • Eleven Years Forecast
  • 7MM Coverage
  • RA Epidemiology Segmentation

Key Questions

  • What is the disease risk, burden and unmet needs of RA?
  • What is the historical RA patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
  • What would be the forecasted patient pool of RA at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to RA?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of RA during the study period (2019–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the study period (2019–2032)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the RA.
  • To understand the future market competition in the RA market and an insightful review of the unmet needs.
  • Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the best opportunities for RA in the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
  • The RA epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources..

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Epidemiology Forecast Flow Methodology

5. RA Overview at a Glance

5.1. Patient Share (%) Distribution of RA in 2019

5.2. Patient Share (%) Distribution of RA in 2032

6. Disease Background and Overview

6.1. Introduction

6.2. Stages of RA

6.3. Types of RA

6.3.1. Seropositive RA

6.3.2. Seronegative RA

6.4. Signs and Symptoms of RA

6.5. Risk Factors and Causes of RA

6.6. Complications of RA

6.7. Pathogenesis of RA

6.7.1. Disease Initiation

6.7.2. Triggers of Disease

6.7.3. Citrullination

6.7.4. Early and established RA

6.7.5. Propagation of Disease

6.8. Diagnosis of RA

6.9. Screening of RA

6.10. Rationale and Impact for investigations following the diagnosis: NICE 2020

6.11. Evaluations of Disease Activity in RA

6.12. American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2010 classification criteria for RA

7. Epidemiology and Patient Population of 7MM

7.1. Epidemiology Methodology

7.2. Key Findings

7.3. Assumptions and Rationale: 7MM

7.4. Epidemiology Scenario: 7MM

7.4.1. Total Prevalent Cases of RA in the 7MM

7.4.2. Total Diagnosed Prevalent Cases of RA in the 7MM

7.4.3. Gender-specific Prevalent Cases of RA in the 7MM

7.4.4. Age-specific Prevalent Cases of RA in the 7MM

7.4.5. Severity-specific Prevalent Cases of RA in the 7MM

7.4.6. Patients on targeted therapies of RA in the 7MM

7.4.7. Line-Wise Treated Cases of RA in the 7MM

7.5. The United States Epidemiology

7.5.1. Total Prevalent Cases of RA in the United States

7.5.2. Total Diagnosed Prevalent Cases of RA in the United States

7.5.3. Gender-specific Prevalent Cases of RA in the United States

7.5.4. Age-specific Prevalent Cases of RA in the United States

7.5.5. Severity-specific Prevalent Cases of RA in the United States

7.5.6. Patients on targeted therapies of RA in the United States

7.5.7. Line-Wise Treated Cases of RA in the United States

7.6. EU4 and UK Epidemiology

7.6.1. Total Prevalent Population of RA in EU4 and the UK

7.6.2. Total Diagnosed Prevalent Cases of RA in EU4 and the UK

7.6.3. Gender-specific Prevalent Cases of RA in EU4 and the UK

7.6.4. Age-specific Prevalent Cases of RA in EU4 and the UK

7.6.5. Severity-specific Prevalent Cases of RA in EU4 and the UK

7.6.6. Patients on targeted therapies of RA in EU4 and the UK

7.6.7. Line-Wise Treated Cases of RA in EU4 and the UK

7.7. Japan Epidemiology

7.7.1. Total Prevalent Cases of RA in Japan

7.7.2. Total Diagnosed Prevalent Cases of RA in Japan

7.7.3. Gender-specific Prevalent Cases of RA in Japan

7.7.4. Age-specific Prevalent Cases of RA in Japan

7.7.5. Severity-specific Prevalent Cases of RA in Japan

7.7.6. Patients on targeted therapies of RA in Japan

7.7.7. Line-Wise Treated Cases of RA in Japan

8 .Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

Table 1: Summary of RA Epidemiology (2019–2032)

Table 2: Total Prevalent Cases of RA in the 7MM (2019–2032)

Table 3: Total Diagnosed Prevalent Cases of RA in the 7MM (2019–2032)

Table 4: Gender-specific Prevalent Cases of RA in the 7MM (2019–2032)

Table 5: Age-specific Prevalent Cases of RA in the 7MM (2019–2032)

Table 6: Severity-specific Prevalent Cases of RA in the 7MM (2019–2032)

Table 7: Patients on targeted therapies of RA in the 7MM (2019–2032)

Table 8: Line-Wise Treated Cases of RA in the 7MM (2019–2032)

Table 9: Total Prevalent Cases of RA in the United States (2019–2032)

Table 10: Total Diagnosed Prevalent Cases of RA in the United States (2019–2032)

Table 11: Gender-specific Prevalent Cases of RA in the United States (2019–2032)

Table 12: Age-specific Prevalent Cases of RA in the United States (2019–2032)

Table 13: Severity-specific Prevalent Cases of RA in the United States (2019–2032)

Table 14: Patients on targeted therapies of RA in the United States (2019–2032)

Table 15: Line-Wise Treated Cases of RA in the United States (2019–2032)

Table 16: Total Prevalent Population of RA in EU4 and the UK (2019–2032)

Table 17: Total of Diagnosed Prevalent Cases of RA in EU4 and the UK (2019–2032)

Table 18: Gender-specific Prevalence of RA in EU4 and the UK (2019–2032)

Table 19: Age-specific Prevalence of RA in EU4 and the UK (2019–2032)

Table 20: Severity-specific Prevalent Cases of RA in EU4 and the UK (2019–2032)

Table 21: Patients on targeted therapies of RA in EU4 and the UK (2019–2032)

Table 22: Line-Wise Treated Cases of RA in EU4 and the UK (2019–2032)

Table 23: Total Prevalent Cases of RA in Japan (2019–2032)

Table 24: Total Diagnosed Prevalent Cases of RA in Japan (2019–2032)

Table 25: Gender-specific Prevalent Cases of RA in Japan (2019–2032)

Table 26: Age-specific Prevalent Cases of RA in Japan (2019–2032)

Table 27: Severity-specific Prevalent Cases of RA in Japan (2019–2032)

Table 28: Patients on targeted therapies of RA in Japan (2019–2032)

Table 29: Line-Wise Treated Cases of RA in Japan (2019–2032)

List of Figures

Figure 1: RA Distressed Area

Figure 2: Bone joint differentiation of normal and RA

Figure 3: Development and progression of RA

Figure 4: Sign and Symptoms of RA

Figure 5: Associations and links for RA

Figure 6: Initiation and Progression of RA

Figure 7: Clinical manifestations of RA

Figure 8: Antinuclear Antibody Test

Figure 9: Clinical Diagnosis of RA

Figure 10: Diagnostic criteria for RA

Figure 11: Screening for Rheumatoid Arthritis

Figure 12: Total Prevalent Cases of RA in the 7MM (2019–2032)

Figure 13: Total Diagnosed Prevalent Cases of RA in the 7MM (2019–2032)

Figure 14: Gender-specific Prevalent Cases of RA in the 7MM (2019–2032)

Figure 15: Age-specific Prevalent Cases of RA in the 7MM (2019–2032)

Figure 16: Severity-specific Prevalent Cases of RA in the 7MM (2019–2032)

Figure 17: Patients on targeted therapies of RA in the 7MM (2019–2032)

Figure 18: Line-Wise Treated Cases of RA in the 7MM (2019–2032)

Figure 19: Total Prevalent Cases of RA in the United States (2019–2032)

Figure 20: Total Diagnosed Prevalent Cases of RA in the United States (2019–2032)

Figure 21: Gender-specific Prevalent Cases of RA in the United States (2019–2032)

Figure 22: Age-specific Prevalent Cases of RA in the United States (2019–2032)

Figure 23: Severity-specific Prevalent Cases of RA in the United States (2019–2032)

Figure 24: Patients on targeted therapies of RA in the United States (2019–2032)

Figure 25: Line-Wise Treated Cases of RA in the United States (2019–2032)

Figure 26: Total Prevalent Cases of RA in EU4 and the UK (2019–2032)

Figure 27: Total Diagnosed Prevalent Cases of RA in EU4 and the UK (2019–2032)

Figure 28: Gender-specific Prevalent Cases of RA in EU4 and the UK (2019–2032)

Figure 29: Age-specific Prevalent Cases of RA in EU4 and the UK (2019–2032)

Figure 30: Severity-specific Prevalent Cases of RA in EU4 and the UK (2019–2032)

Figure 31: Patients on targeted therapies of RA in EU4 and the UK (2019–2032)

Figure 32: Line-Wise Treated Cases of RA in EU4 and the UK (2019–2032)

Figure 33: Total Prevalent Cases of RA in Japan (2019–2032)

Figure 34: Total Diagnosed Prevalent Cases of RA in Japan (2019–2032)

Figure 35: Gender-specific Prevalent Cases of RA in Japan (2019–2032)

Figure 36: Age-specific Prevalent Cases of RA in Japan (2019–2032)

Figure 37: Severity-specific Prevalent Cases of RA in Japan (2019–2032)

Figure 38: Patients on targeted therapies of RA in Japan (2019–2032)

Figure 39: Line-Wise Treated Cases of RA in Japan (2019–2032)

Forward to Friend

Need A Quote